

Helping life science companies manage their financial and professional risks

An evolving insurance market, intensifying regulatory scrutiny, and a heightened probability of litigation are just some of the challenges for directors and officers of life science companies today. Tackling this complex risk environment requires the support of trusted advisors with experience, knowledge, and a proven track record.

Marsh FINPRO's Life Science Center of Excellence (COE) is uniquely positioned to deliver unmatched results. This dedicated global group is comprised of colleagues with experience working as underwriters, attorneys, and brokers in key markets, including the US, London, Canada, and Bermuda. These varied and global perspectives allow us to provide insight into the key risks facing life science companies of all types and sizes, from small medical device and pre-clinical drug companies to multinational biopharma conglomerates.

We can deliver superior knowledge of all key financial and professional coverages, including:

- Directors and officers liability (D&O).
- Cyber and professional liability.
- Employment practices liability (EPL).
- Fidelity/crime.
- Fiduciary liability
- Special risk (K&R).

LIFE SCIENCE COMPANIES' UNIQUE RISK CHALLENGES

- Binary events.
- SEC and FDA feedback and disclosure-related activities.
- FINRA notices.
- Trolling law firms.
- Transactions and fundraising — SPACS, deSPACS, IPOs, secondary offerings, mergers, and more.

22%

of federal securities class-action suits in 2020 were filed against health technology and services companies, according to NERA Economic Consulting.

Why Marsh?

- **Robust process:** A dedicated life science COE and **300+** US FINPRO professionals who understand the nuances of your business and can help you differentiate your risk profile and execute renewal strategies.
- **Experience:** **400 financial and professional claims** annually, including **1 in 4 securities settlements**, giving us insight into common claim sources.
- **Global collaboration:** **1,000+** FINPRO colleagues worldwide who deliver optimal results by sharing knowledge, ideas, and best practices.
- **Innovative analytics:** Insurance coverage designed and tailored to meet your specific needs, using IDEAL — our unique predictive D&O claims modeling tool — and deep life science benchmarking data from:
 - **70%** of the top 50 global pharmaceutical companies.
 - **44%** of the top 50 global biotech companies.
 - **50%** of the top 10 public contract research organizations.
 - **60%** of the top 40 global medical device manufacturers.
- **Claims advocacy:** **15** dedicated, life science industry-focused claims advocates who have negotiated **\$4B+** in claims settlements since 2010, working with leading law firms to navigate even the most complex claims.
- **Scale and relationships:** **\$8.6B+** in financial and professional liability premiums placed annually, relationships with all leading insurers, and knowledge of individual market appetites, enabling us to effectively present and differentiate your risk profile.

About Marsh

Marsh is the world's leading insurance broker and risk advisor. With around 40,000 colleagues operating in more than 130 countries, Marsh serves commercial and individual clients with data-driven risk solutions and advisory services. Marsh is a business of Marsh McLennan (NYSE: MMC), the world's leading professional services firm in the areas of risk, strategy and people. With annual revenue over \$17 billion, Marsh McLennan helps clients navigate an increasingly dynamic and complex environment through four market-leading businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. For more information, visit mmc.com, follow us on [LinkedIn](#) and [Twitter](#) or subscribe to [BRINK](#).

Marsh is one of the Marsh & McLennan Companies, together with Guy Carpenter, Mercer, and Oliver Wyman.

This document and any recommendations, analysis, or advice provided by Marsh (collectively, the "Marsh Analysis") are not intended to be taken as advice regarding any individual situation and should not be relied upon as such. The information contained herein is based on sources we believe reliable, but we make no representation or warranty as to its accuracy. Marsh shall have no obligation to update the Marsh Analysis and shall have no liability to you or any other party arising out of this publication or any matter contained herein. Any statements concerning actuarial, tax, accounting, or legal matters are based solely on our experience as insurance brokers and risk consultants and are not to be relied upon as actuarial, tax, accounting, or legal advice, for which you should consult your own professional advisors. Any modeling, analytics, or projections are subject to inherent uncertainty, and the Marsh Analysis could be materially affected if any underlying assumptions, conditions, information, or factors are inaccurate or incomplete or should change. Marsh makes no representation or warranty concerning the application of policy wording or the financial condition or solvency of insurers or reinsurers. Marsh makes no assurances regarding the availability, cost, or terms of insurance coverage. Although Marsh may provide advice and recommendations, all decisions regarding the amount, type or terms of coverage are the ultimate responsibility of the insurance purchaser, who must decide on the specific coverage that is appropriate to its particular circumstances and financial position.

Contacts



Kerri Petri
Senior Vice President
Co-Leader,
FINPRO Life Science
+1 617 385 0398
kerri.petri@marsh.com



Bryan Berkman
Managing Director
Co-Leader,
FINPRO Life Science
+1 914 843 1928
bryan.berkman@marsh.com